Use of aromatase inhibitors in patients with breast cancer is associated with deterioration of bone microarchitecture and density
Autor(a) principal: | |
---|---|
Data de Publicação: | 2021 |
Outros Autores: | , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Arquivos de Endocrinologia e Metabolismo (Online) |
Texto Completo: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S2359-39972021000400505 |
Resumo: | ABSTRACT Objective: To evaluate changes in bone density and architecture in postmenopausal women with breast cancer (BC) and use of aromatase inhibitor (AI). Subjects and methods: Thirty-four postmenopausal women with BC, without bone metastasis, renal function impairment and who were not receiving bone-active drugs were selected from a population of 523 outpatients treated for BC. According to the presence of hormonal receptors, HER2 and Ki67, seventeen had positive hormonal receptors and received anastrozole (AI group), and seventeen were triple-negative receptors (non-AI group), previously treated with chemotherapy. Areal bone mineral density (aBMD) and vertebral fracture assessment (VFA) analyses were performed by DXA; vBMD and bone microarchitecture were evaluated by HR-pQCT. Fracture risk was estimated using the FRAX tool. Results: No patient referred previous low-impact fracture, and VFA detected one moderate vertebral fracture in a non-AI patient. AI patients showed lower aBMD and BMD T-scores at the hip and 33% radius and a higher proportion of osteoporosis diagnosis on DXA (47%) vs non-AI (17.6%). AI group had significantly lower values for vBMD at the entire, cortical and trabecular bone compartments, cortical and trabecular thickness and BV/TV. They also had a higher risk for major fractures and for hip fractures estimated by FRAX. Several HR-pQCT parameters evaluated at distal radius and distal tibia were significantly associated with fracture risk. Conclusion: AI is associated with alterations in bone density and microarchitecture of both the cortical and trabecular compartments. These findings explain the overall increase in fracture risk in this specific population. |
id |
SBEM-1_ba53c4d7b201243bd81ce1f9ab6177a4 |
---|---|
oai_identifier_str |
oai:scielo:S2359-39972021000400505 |
network_acronym_str |
SBEM-1 |
network_name_str |
Arquivos de Endocrinologia e Metabolismo (Online) |
repository_id_str |
|
spelling |
Use of aromatase inhibitors in patients with breast cancer is associated with deterioration of bone microarchitecture and densityBreast cancerosteoporosisaromatase inhibitors (AI)bone mineral density (BMD)high resolution peripheral quantitative computed tomography (HR-pQCT)ABSTRACT Objective: To evaluate changes in bone density and architecture in postmenopausal women with breast cancer (BC) and use of aromatase inhibitor (AI). Subjects and methods: Thirty-four postmenopausal women with BC, without bone metastasis, renal function impairment and who were not receiving bone-active drugs were selected from a population of 523 outpatients treated for BC. According to the presence of hormonal receptors, HER2 and Ki67, seventeen had positive hormonal receptors and received anastrozole (AI group), and seventeen were triple-negative receptors (non-AI group), previously treated with chemotherapy. Areal bone mineral density (aBMD) and vertebral fracture assessment (VFA) analyses were performed by DXA; vBMD and bone microarchitecture were evaluated by HR-pQCT. Fracture risk was estimated using the FRAX tool. Results: No patient referred previous low-impact fracture, and VFA detected one moderate vertebral fracture in a non-AI patient. AI patients showed lower aBMD and BMD T-scores at the hip and 33% radius and a higher proportion of osteoporosis diagnosis on DXA (47%) vs non-AI (17.6%). AI group had significantly lower values for vBMD at the entire, cortical and trabecular bone compartments, cortical and trabecular thickness and BV/TV. They also had a higher risk for major fractures and for hip fractures estimated by FRAX. Several HR-pQCT parameters evaluated at distal radius and distal tibia were significantly associated with fracture risk. Conclusion: AI is associated with alterations in bone density and microarchitecture of both the cortical and trabecular compartments. These findings explain the overall increase in fracture risk in this specific population.Sociedade Brasileira de Endocrinologia e Metabologia2021-08-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S2359-39972021000400505Archives of Endocrinology and Metabolism v.65 n.4 2021reponame:Arquivos de Endocrinologia e Metabolismo (Online)instname:Sociedade Brasileira de Endocrinologia e Metabologia (SBEM)instacron:SBEM10.20945/2359-3997000000385info:eu-repo/semantics/openAccessNunes,Frederico Arthur PereiraFarias,Maria Lucia Fleiuss deOliveira,Felipe PeresVieira Neto,LeonardoLima,Luis Felipe CardosoParanhos Neto,Francisco de PaulaMendonça,Laura Maria Carvalho deMadeira,Migueleng2021-09-16T00:00:00Zoai:scielo:S2359-39972021000400505Revistahttps://www.aem-sbem.com/https://old.scielo.br/oai/scielo-oai.php||aem.editorial.office@endocrino.org.br2359-42922359-3997opendoar:2021-09-16T00:00Arquivos de Endocrinologia e Metabolismo (Online) - Sociedade Brasileira de Endocrinologia e Metabologia (SBEM)false |
dc.title.none.fl_str_mv |
Use of aromatase inhibitors in patients with breast cancer is associated with deterioration of bone microarchitecture and density |
title |
Use of aromatase inhibitors in patients with breast cancer is associated with deterioration of bone microarchitecture and density |
spellingShingle |
Use of aromatase inhibitors in patients with breast cancer is associated with deterioration of bone microarchitecture and density Nunes,Frederico Arthur Pereira Breast cancer osteoporosis aromatase inhibitors (AI) bone mineral density (BMD) high resolution peripheral quantitative computed tomography (HR-pQCT) |
title_short |
Use of aromatase inhibitors in patients with breast cancer is associated with deterioration of bone microarchitecture and density |
title_full |
Use of aromatase inhibitors in patients with breast cancer is associated with deterioration of bone microarchitecture and density |
title_fullStr |
Use of aromatase inhibitors in patients with breast cancer is associated with deterioration of bone microarchitecture and density |
title_full_unstemmed |
Use of aromatase inhibitors in patients with breast cancer is associated with deterioration of bone microarchitecture and density |
title_sort |
Use of aromatase inhibitors in patients with breast cancer is associated with deterioration of bone microarchitecture and density |
author |
Nunes,Frederico Arthur Pereira |
author_facet |
Nunes,Frederico Arthur Pereira Farias,Maria Lucia Fleiuss de Oliveira,Felipe Peres Vieira Neto,Leonardo Lima,Luis Felipe Cardoso Paranhos Neto,Francisco de Paula Mendonça,Laura Maria Carvalho de Madeira,Miguel |
author_role |
author |
author2 |
Farias,Maria Lucia Fleiuss de Oliveira,Felipe Peres Vieira Neto,Leonardo Lima,Luis Felipe Cardoso Paranhos Neto,Francisco de Paula Mendonça,Laura Maria Carvalho de Madeira,Miguel |
author2_role |
author author author author author author author |
dc.contributor.author.fl_str_mv |
Nunes,Frederico Arthur Pereira Farias,Maria Lucia Fleiuss de Oliveira,Felipe Peres Vieira Neto,Leonardo Lima,Luis Felipe Cardoso Paranhos Neto,Francisco de Paula Mendonça,Laura Maria Carvalho de Madeira,Miguel |
dc.subject.por.fl_str_mv |
Breast cancer osteoporosis aromatase inhibitors (AI) bone mineral density (BMD) high resolution peripheral quantitative computed tomography (HR-pQCT) |
topic |
Breast cancer osteoporosis aromatase inhibitors (AI) bone mineral density (BMD) high resolution peripheral quantitative computed tomography (HR-pQCT) |
description |
ABSTRACT Objective: To evaluate changes in bone density and architecture in postmenopausal women with breast cancer (BC) and use of aromatase inhibitor (AI). Subjects and methods: Thirty-four postmenopausal women with BC, without bone metastasis, renal function impairment and who were not receiving bone-active drugs were selected from a population of 523 outpatients treated for BC. According to the presence of hormonal receptors, HER2 and Ki67, seventeen had positive hormonal receptors and received anastrozole (AI group), and seventeen were triple-negative receptors (non-AI group), previously treated with chemotherapy. Areal bone mineral density (aBMD) and vertebral fracture assessment (VFA) analyses were performed by DXA; vBMD and bone microarchitecture were evaluated by HR-pQCT. Fracture risk was estimated using the FRAX tool. Results: No patient referred previous low-impact fracture, and VFA detected one moderate vertebral fracture in a non-AI patient. AI patients showed lower aBMD and BMD T-scores at the hip and 33% radius and a higher proportion of osteoporosis diagnosis on DXA (47%) vs non-AI (17.6%). AI group had significantly lower values for vBMD at the entire, cortical and trabecular bone compartments, cortical and trabecular thickness and BV/TV. They also had a higher risk for major fractures and for hip fractures estimated by FRAX. Several HR-pQCT parameters evaluated at distal radius and distal tibia were significantly associated with fracture risk. Conclusion: AI is associated with alterations in bone density and microarchitecture of both the cortical and trabecular compartments. These findings explain the overall increase in fracture risk in this specific population. |
publishDate |
2021 |
dc.date.none.fl_str_mv |
2021-08-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S2359-39972021000400505 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S2359-39972021000400505 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
10.20945/2359-3997000000385 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
text/html |
dc.publisher.none.fl_str_mv |
Sociedade Brasileira de Endocrinologia e Metabologia |
publisher.none.fl_str_mv |
Sociedade Brasileira de Endocrinologia e Metabologia |
dc.source.none.fl_str_mv |
Archives of Endocrinology and Metabolism v.65 n.4 2021 reponame:Arquivos de Endocrinologia e Metabolismo (Online) instname:Sociedade Brasileira de Endocrinologia e Metabologia (SBEM) instacron:SBEM |
instname_str |
Sociedade Brasileira de Endocrinologia e Metabologia (SBEM) |
instacron_str |
SBEM |
institution |
SBEM |
reponame_str |
Arquivos de Endocrinologia e Metabolismo (Online) |
collection |
Arquivos de Endocrinologia e Metabolismo (Online) |
repository.name.fl_str_mv |
Arquivos de Endocrinologia e Metabolismo (Online) - Sociedade Brasileira de Endocrinologia e Metabologia (SBEM) |
repository.mail.fl_str_mv |
||aem.editorial.office@endocrino.org.br |
_version_ |
1752122518069575680 |